Sanford Community Cancer Consortium

$524,344U10FY2011CANIH

Sanford Research/Usd, Fargo SD

Investigators

Linked publications & trials

Paper 29164377 Paper 28921241 Paper 28786105 Paper 28089762 Paper 27825638 Paper 27534963 Paper 27075674 Paper 25423327 Paper 25043153 Paper 24060820 Paper 23853057 Paper 23833308 Paper 23748483 Paper 23543373 Paper 23357973 Paper 23151649 Paper 23150188 Paper 22915053 Paper 22815703 Paper 22572824 Paper 22415454 Paper 21900849 Paper 21729678 Paper 21702402 Paper 21673350 Paper 21479990 Paper 21472717 Paper 21383290 Paper 21383282 Paper 21345074 Paper 21218460 Paper 21060036 Paper 20820817 Paper 20798191 Paper 20552926 Paper 20510539 Paper 20498389 Paper 20496177 Paper 20209614 Paper 20126980 Paper 20063115 Paper 19935387 Paper 19901102 Paper 19884856 Paper 19739269 Paper 19546817 Paper 19415341 Paper 19380443 Paper 19349549 Paper 19129205 Paper 19087987 Paper 19066728 Paper 19060590 Paper 19047293 Paper 18955445 Paper 18768432 Paper 18569634 Paper 18543329 Paper 18470909 Paper 18449005 Paper 18045731 Paper 17853395 Paper 17634491 Paper 17577035 Paper 17470735 Paper 17401014 Paper 17320666 Paper 17146104 Paper 17022922 Paper 16945169 Paper 16921039 Paper 16858161 Paper 16782922 Paper 16770976 Paper 16755177 Paper 16730134 Paper 16538529 Paper 16505427 Paper 16505423 Paper 16505409 Paper 16303863 Paper 16230673 Paper 16185755 Paper 16085692 Paper 15912493 Paper 15852407 Paper 15803016 Paper 15611509 Paper 15558814 Paper 15278681 Paper 15254052 Paper 15234027 Paper 15197210 Paper 15140548 Paper 14528068 Paper 14505160 Paper 12796591 Paper 12794247 Paper 12794246 Paper 12745490

Abstract

DESCRIPTION (provided by applicant): CCOP Goals and Objectives (2009-2014) The overall goal of MeritCare Hospital CCOP is to provide state-of-the-art cancer care to patients and families, as close to home as possible, through participation in National Cancer Institute (NCI) approved clinical trials. Program Objectives: 1) Increase the number of eligible patients place on NCI approved cancer treatment clinical research trials. 2) Facilitate wider community participation, including minorities, women, and other underserved populations in cancer treatment, prevention, and control research approved by NCI. 3) Continue to enhance the participation of primary healthcare providers and other specialist with the CCOP investigators in cancer treatment and control research. 4) Increase the quality and efficiency of data management systems/processes. 5) Expand participation in NCI approved cancer prevention and control clinical research trials.

View original record on NIH RePORTER →